Readers will recall that the Centers for Medicare and Medicaid Services announced Novartis' Entresto as one of the first 10 medicines in the Medicare Drug Price Negotiation Program for 2026.

In its lawsuit, the company argued the U.S. Health Resources and Services Administration wrongfully interpreted a federal law concerning the use of rebates in the program. Novartis sells the ...

Novartis shareholders elected Giovanni Caforio as new member and Chair of the Board of Directors as well as Elizabeth McNally as new member of the Board of Directors. Joerg Reinhardt, Charles L.

Also Read: Novartis To Beef Up Heart Disease Offering ... expanded this model by granting the Department of Health and Human Services (HHS) similar authority to negotiate prices for Medicare ...

Novartis AG is a holding company ... The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel ...

Novartis AG (NYSE:NVS) reportedly plans to slash up to 680 positions in its development organization, aiding in drug market launches. The Basel-based company announced that approximately 440 ...

Q4 2024 results exceeded expectations with 16% net sales growth and a 55% increase in operating income, supporting Novartis' EPS growth trajectory. The acquisition of Anthos Therapeutics and ...

ZURICH, Feb 26 (Reuters) - The investment vehicle of the Sandoz family will get 2.6 billion Swiss francs ($2.90 billion) from selling a chunk of Swiss pharma giant Novartis (NOVN.S), opens new tab ...